122 related articles for article (PubMed ID: 37826938)
21. Development and Verification of a Linked
Patilea-Vrana GI; Unadkat JD
Drug Metab Dispos; 2021 Jul; 49(7):509-520. PubMed ID: 33952608
[TBL] [Abstract][Full Text] [Related]
22. Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors.
Pilla Reddy V; Fretland AJ; Zhou D; Sharma S; Chen B; Vishwanathan K; McGinnity DF; Xu Y; Ware JA
Cancer Chemother Pharmacol; 2021 Sep; 88(3):451-464. PubMed ID: 34080039
[TBL] [Abstract][Full Text] [Related]
23. Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.
Song L; Zhang Y; Jiang J; Ren S; Chen L; Liu D; Chen X; Hu P
Clin Pharmacokinet; 2018 Oct; 57(10):1307-1323. PubMed ID: 29626326
[TBL] [Abstract][Full Text] [Related]
24. Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models.
Björkman S
J Pharmacokinet Pharmacodyn; 2003 Aug; 30(4):285-307. PubMed ID: 14650375
[TBL] [Abstract][Full Text] [Related]
25. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban.
Willmann S; Becker C; Burghaus R; Coboeken K; Edginton A; Lippert J; Siegmund HU; Thelen K; Mück W
Clin Pharmacokinet; 2014 Jan; 53(1):89-102. PubMed ID: 23912563
[TBL] [Abstract][Full Text] [Related]
26. Physiologically based pharmacokinetic modelling to predict single- and multiple-dose human pharmacokinetics of bitopertin.
Parrott N; Hainzl D; Alberati D; Hofmann C; Robson R; Boutouyrie B; Martin-Facklam M
Clin Pharmacokinet; 2013 Aug; 52(8):673-83. PubMed ID: 23591780
[TBL] [Abstract][Full Text] [Related]
27. Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro-in vivo extrapolation.
Algharably EAE; Di Consiglio E; Testai E; Kreutz R; Gundert-Remy U
Arch Toxicol; 2021 Apr; 95(4):1433-1442. PubMed ID: 33606068
[TBL] [Abstract][Full Text] [Related]
28. Computational modeling to predict effect of treatment schedule on drug delivery to prostate in humans.
Hu L; Au JL; Wientjes MG
Clin Cancer Res; 2007 Feb; 13(4):1278-87. PubMed ID: 17317840
[TBL] [Abstract][Full Text] [Related]
29. Predictive Performance of Physiologically Based Pharmacokinetic Modelling of Beta-Lactam Antibiotic Concentrations in Adipose, Bone, and Muscle Tissues.
De Sutter PJ; De Cock P; Johnson TN; Musther H; Gasthuys E; Vermeulen A
Drug Metab Dispos; 2023 Apr; 51(4):499-508. PubMed ID: 36639242
[TBL] [Abstract][Full Text] [Related]
30. A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans.
Bi Y; Deng J; Murry DJ; An G
AAPS J; 2016 Jan; 18(1):228-38. PubMed ID: 26559435
[TBL] [Abstract][Full Text] [Related]
31. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex.
Conner TM; Nikolian VC; Georgoff PE; Pai MP; Alam HB; Sun D; Reed RC; Zhang T
Eur J Pharm Sci; 2018 Jan; 111():465-481. PubMed ID: 29030176
[TBL] [Abstract][Full Text] [Related]
32. Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.
Xia B; Heimbach T; Lin TH; He H; Wang Y; Tan E
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1567-82. PubMed ID: 22526410
[TBL] [Abstract][Full Text] [Related]
33. Bayesian evaluation of a physiologically based pharmacokinetic (PBPK) model for perfluorooctane sulfonate (PFOS) to characterize the interspecies uncertainty between mice, rats, monkeys, and humans: Development and performance verification.
Chou WC; Lin Z
Environ Int; 2019 Aug; 129():408-422. PubMed ID: 31152982
[TBL] [Abstract][Full Text] [Related]
34. Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics.
Adiwidjaja J; Boddy AV; McLachlan AJ
Front Pharmacol; 2019; 10():1672. PubMed ID: 32082165
[TBL] [Abstract][Full Text] [Related]
35. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
Peters SA
Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
[TBL] [Abstract][Full Text] [Related]
36. Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling.
Verheijen M; Schrooders Y; Gmuender H; Nudischer R; Clayton O; Hynes J; Niederer S; Cordes H; Kuepfer L; Kleinjans J; Caiment F
Toxicol Lett; 2018 Sep; 294():184-192. PubMed ID: 29803840
[TBL] [Abstract][Full Text] [Related]
37. Risk assessment in extrapolation of pharmacokinetics from preclinical data to humans.
Teitelbaum Z; Lave T; Freijer J; Cohen AF
Clin Pharmacokinet; 2010 Sep; 49(9):619-32. PubMed ID: 20690784
[TBL] [Abstract][Full Text] [Related]
38. Application of population physiologically based pharmacokinetic modelling to optimize target expression and clearance mechanisms of therapeutic monoclonal antibodies.
Reig-Lopez J; Tang W; Fernandez-Teruel C; Merino-Sanjuan M; Mangas-Sanjuan V; Boulton DW; Sharma P
Br J Clin Pharmacol; 2023 Sep; 89(9):2691-2702. PubMed ID: 37055941
[TBL] [Abstract][Full Text] [Related]
39. Investigation of the influence of modulation of P-glycoprotein by a multiple dosing regimen of tamoxifen on the pharmacokinetics and toxicodynamics of doxorubicin.
Darvari R; Boroujerdi M
Cancer Chemother Pharmacol; 2005 Nov; 56(5):497-509. PubMed ID: 15937726
[TBL] [Abstract][Full Text] [Related]
40. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
